Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ValiRx plc ( (GB:VAL) ) just unveiled an update.
ValiRx has entered into a new evaluation and option agreement with Altus Formulation to explore the potential of Altus’ SmartCelle drug delivery technologies in cancer treatment. This collaboration will assess the technology’s ability to improve drug solubility, potency, and targeting, with ValiRx having the option to license these technologies for certain cancers. The agreement is expected to expand ValiRx’s capabilities in drug development and enhance its positioning in oncology, offering potential benefits for stakeholders by accelerating the development of innovative cancer therapeutics.
More about ValiRx plc
ValiRx is a life sciences company that concentrates on early-stage cancer therapeutics and women’s health. The company aims to expedite the translation of innovative science into effective medicines to enhance patient lives. ValiRx leverages its expertise in research and drug development to select and incubate promising drug candidates, guiding them through an optimized development process from pre-clinical stages to market-ready assets. Furthermore, ValiRx collaborates with a range of partners to streamline the drug development process and reduce costs.
YTD Price Performance: 2.56%
Average Trading Volume: 9,529,092
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.99M
See more insights into VAL stock on TipRanks’ Stock Analysis page.
